Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc. Show more

42127 Pleasant Forest Court, Ashburn, VA, 20148-7349, United States

Biotechnology
Healthcare

Market Cap

13.03M

52 Wk Range

$5.01 - $41.80

Previous Close

$8.06

Open

$7.89

Volume

2,924

Day Range

$7.80 - $8.49

Enterprise Value

7.614M

Cash

5.413M

Avg Qtr Burn

-2.225M

Insider Ownership

3.54%

Institutional Own.

59.02%

Qtr Updated

09/30/25